TEAM
Third Eye is founded on the basic principles of constant self-reflection and the ability to adapt our ideas to the latest scientific advances.
OUR TEAM
SACHIN SONI
Co-founder & Fund Manager
Sachin Soni is the promoter, co-founder and fund manager of Third Eye. Prior to incorporating Third Eye in 2016, Sachin worked as an equity research analyst on the Life Sciences team in the Securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands, and became a Director and Head of the Life Sciences team. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European Healthcare/Life Sciences sector and won Extel and Starmine awards for stock picking. He has fifteen years of experience in Life Sciences, with an exposure to both private (venture capital) as well as public market investments and has been involved in multiple IPO's and secondary transactions, raising over €1.0bn for various life sciences companies.
Sachin was ranked among the top 0.1% of students at the All-India level in Physics and Chemistry, won a national scholarship and finished his degree in Medicine (MBBS) with distinctions in Pharmacology and Biochemistry from Seth G S Medical College & KEM Hospital, Mumbai, India. He then started his career as a medical doctor, working from 2004 to 2006 as a general practitioner with the Indian Red Cross and Max Healthcare Hospital. Then in 2008 he obtained his Master of Business Administration (MBA), with concentration in finance, from the Rotterdam School of Management at Erasmus University (the Netherlands) and Columbia Business School (USA).
MARK POSPSILIK
Co-founder & Fund Manager
Mark Pospisilik is co-founder and fund manager of Third Eye. Prior to setting up Third Eye, Mark worked as a senior equity research analyst on the Life Sciences team in the Securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands. He has over fifteen years of work experience and of that more than eight years of experience in Life Sciences equity markets, analyzing companies across the technology spectrum, including therapeutics, diagnostics and medical devices. During his time with Kempen & Co from 2010 to 2016, he contributed to the coverage of over 30 listed European Life Sciences companies, and was involved in numerous IPO's and secondary financings.
Mark entered the Faculty of Science at the University of British Columbia (Canada) on an entrance scholarship, was eventually named to the Dean’s Honour List, and obtained his Bachelor of Science (Life Science) degree in 1997. He then studied law at the University of British Columbia and at La Pontificia Universidad Catholica (Chile), obtaining his Juris Doctor in 2000. Mark started his career as an intellectual property lawyer at Vermette & Co, in Vancouver, Canada, where he enabled technology companies to obtain patent protection in Canada, the US, Europe and Japan, and to enforce and licence their patent and trademark rights globally. During this time he also obtained qualification as a Registered Patent Agent and Registered Trademark Agent before the Canadian Intellectual Property Office (CIPO) and the US Patent and Trademark Office (USPTO). Mark then switched to finance, obtaining his Master of Business Administration (MBA), with concentration in finance, from the Rotterdam School of Management at Erasmus University (the Netherlands) in 2010.
OUR ADVISORS
RICHARD VAN DEN BROEK
Fund Advisor
Mr. van den Broek is Founder and Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry since 2004. From 2000 through 2003, he served as a Partner of Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to working for Cooper Hill Partners, LLC, Mr. van den Broek had a 10-year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist. Mr. van den Broek graduated from Harvard University and is a Chartered Financial Analyst.
Mr. van den Broek has extensive board experience. He currently sits on the Board of Directors of Cogstate, Inc. Previously he was a Director of Pharmacyclics Inc. from December 2009 until its acquisition by AbbVie for $21bn in 2015. Additionally in the past he has served as a director at Pharmaxis and Strategic Diagnostics, among others.